Scheduled Conference Calls and Product Launches - Research Reports on Anika Therapeutics, NeoGenomics, HeartWare, Sangamo and Dyax

NEW YORK, July 23, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Anika Therapeutics, Inc. (NASDAQ: ANIK), NeoGenomics, Inc. (NASDAQ: NEO), HeartWare International Inc (NASDAQ: TWR), Sangamo BioSciences, Inc. (NASDAQ: SGMO) and Dyax Corp (NASDAQ: DYAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5011-100free.

--
Anika Therapeutics, Inc. Research Reports
On July 15, 2014, Anika Therapeutics, Inc. (Anika Therapeutics) announced plans to issue its Q2 2014 financial results on Wednesday, July 30, 2014, after the market closes, followed by a conference call on Thursday, July 31, 2014, at 9:00 a.m. ET to discuss the results as well as the Company's business highlights and outlook. Additionally, the Company will take questions about business and financial developments and trends, and other matters, some of the responses to which may contain information that has not been previously disclosed. According to the Company, a live audio webcast of the call will be available on its website, where an archived version of the webcast will also be available shortly after the completion of the live call. The full research reports on Anika Therapeutics are available to download free of charge at:

http://www.analystsreview.com/Jul-23-2014/ANIK/report.pdf

--
NeoGenomics, Inc. Research Reports
On July 11, 2014, NeoGenomics, Inc. (NeoGenomics) announced the launch of 23 new and innovative NeoTYPE™ Cancer Profiles based on next-generation sequencing (NGS) that provides oncologists and pathologists a more targeted and comprehensive ability to tailor cancer testing to an individual patient's needs than has ever been available before. The Company stated that the NeoTYPE™ solid tumor tests are designed to provide precise and comprehensive coverage of actionable molecular abnormalities found specifically in the tested tumor, and are available for Brain, Breast, Cervix, Colorectal, Endometrial, Esophageal, Gastrointestinal Stromal (GIST), Lung, Melanoma, Ovarian, Soft Tissue, Thyroid, and other solid tumors. Douglas VanOort, Chairman and CEO, NeoGenomics, said, "We have worked hard to develop an innovative and unique approach, using multiple technologies, plasma testing, expert result interpretation and reporting, and other tools to make cancer testing efficient for our health care system and informative for physicians and patients." The full research reports on NeoGenomics are available to download free of charge at:

http://www.analystsreview.com/Jul-23-2014/NEO/report.pdf

--
HeartWare International Inc Research Reports
On July 17, 2014, HeartWare International Inc (HeartWare) announced that it will host a conference call to discuss its Q2 2014 financial results on Thursday, July 31, 2014, at 8:00 a.m. EDT, following the release of the financial results earlier that day. HeartWare stated that a live webcast of the call will be available on the Company's website, where a replay of the call will also be available immediately after the completion of the call. The full research reports on HeartWare are available to download free of charge at:

http://www.analystsreview.com/Jul-23-2014/TWR/report.pdf

--
Sangamo BioSciences, Inc. Research Reports
On July 16, 2014, Sangamo BioSciences, Inc. (Sangamo) reported that it has scheduled the release of its Q2 2014 financial results on Wednesday, July 23, 2014, after the market closes, followed by a conference call on the same day at 5:00 p.m. ET to review the quarter's financial results and discuss other new business developments. According to the Company, a live webcast of the call can be accessed through Sangamo's website. A replay of the webcast will also be available on the Company's website beginning at approximately 8:00 a.m. ET on July 23, 2014 through 11:59 p.m. ET on July 30, 2014. The full research reports on Sangamo are available to download free of charge at:

http://www.analystsreview.com/Jul-23-2014/SGMO/report.pdf

--
Dyax Corp Research Reports
On July 15, 2014, Dyax Corp. (Dyax) announced that it will host a conference call, including an open question and answer session, on Tuesday, July 29, 2014, at 5:00 p.m. ET, to discuss the Company's Q2 2014 financial results as well as its progress regarding its key value drivers - the KALBITOR® (ecallantide) business, DX-2930, and the Licensing and Funded Research Portfolio. According to the Company, the call will be webcast via its website. An archived version of the webcast will also be available on Dyax's website where it will remain accessible for an indefinite period of time. The full research reports on Dyax are available to download free of charge at:

http://www.analystsreview.com/Jul-23-2014/DYAX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED